We believe that breakthrough medicines and a coordinated strategy can solve the addiction crisis at scale
Here’s what makes CASPR different.
Clinicians, scientists, and informed policy makers agree that addiction is a disease and we are facing a public health emergency. But compared to diseases with comparable public health burdens, like cancer and heart disease, the US invests 95% less towards the development of new treatments for addiction. And unlike our response to other urgent public health crises, like COVID or HIV/AIDS, we are not acting rapidly and with a coordinated focus to get breakthrough medications into the hands of doctors and patients.
CASPR — the Center for Addiction Science, Policy, and Research — is focused on large-scale strategic opportunities in policy and practice that can permanently reduce the cascade of harms from addiction to a fraction of its current size.
We believe that the addiction crisis, both the new and urgent threats of fentanyl and methamphetamine overdoses and also the older grinding scourges of alcohol and nicotine addiction, can be solved at scale if we bring urgency, political strategy, and coordination to the challenge.
By now, you should be a little skeptical. Addiction is an entrenched multifactorial morass that’s grown much worse over the past decade-- what hasn’t already been tried that could make a big difference over a short time horizon? We just ask that you read our research and proposals and see if you agree that there’s a dramatically better path available.
CASPR’s goal is to drive system-wide change. We aren’t here to help cope with the addiction crisis or gradually chip away at the problem, we are here to fight it and we are here to win.
Donate
If you’d like to support our work, you can donate here. We are a 501c3 tax-deductible non-profit organization, entirely funded by individuals and public foundations. We have no financial support, directly or indirectly, from pharmaceutical companies.
Why might CASPR be worth your support? We are a high-impact organization, relentlessly focused on bring a strategic approach to the field of addiction medicine and getting new treatments to patients as soon as possible. Our background is in startups, tech, science, and medicine-- we are here to move fast and make change at scale. If you are considering a larger donation, please reach out. We’d love to tell you more about our approach and operations.
Our publication, Recursive Adaptation, has over 5,000 subscribers, primarily researchers and practitioners in addiction medicine.
SELECTED ARTICLES
FDA standards for addiction medicine studies are discouraging the development of medications →
Nicholas Reville November 4, 2024
The Medical Evidence for Using Ozempic and GLP-1s for Addiction →
Nicholas Reville, Zarinah Agnew, PhD May 14, 2024
GRACE: Proposing a new GLP-1 based harm reduction strategy →
Nicholas Reville July 25, 2024
A Federal Moonshot for Better Addiction Medications Can Help Us Escape the Crisis →
Nicholas Reville April 14, 2024
"Growing concerns" that Ozempic will disrupt big tobacco, candy companies, and alcohol brands, according to Morgan Stanley →
Nicholas Reville April 26, 2024
OUR TEAM
Cofounder, Executive Director
reville@caspr.org
Cofounder, Managing Director
holden@caspr.org
Research Manager, Data Scientist
elabd@caspr.org
Researcher, Public Health
fong-minhas@caspr.org
Researcher, Computational Biology
kubali@caspr.org
Public Health Researcher
Design Director
saraf@caspr.org
Researcher, Data Scientist
einsiedler@caspr.org
ADVISORY BOARD
Stanford University
Alex Jutca, MPP
Allegheny County Department of Human Services
Paul Niehaus, PhD
GiveDirectly
Sona Chandra, MPH
Pangea Bio
Will Bainbridge
Premier Consulting
Professor Emeritus, University of Pennsylvania
Ned Nunes, MD
Columbia University
Tom Hudzik, PhD
ALA+ BioPharma Consulting
Maya Durvasula
Stanford University